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Dexmedetomidine Inhibits TLR4/
NF-κB Activation and Reduces 
Acute Kidney Injury after 
Orthotopic Autologous Liver 
Transplantation in Rats
Hui Yao1,*, Xinjin Chi1,*, Yi Jin2, Yiheng Wang1,3, Pinjie Huang1, Shan Wu1, Zhengyuan Xia4 & 
Jun Cai1
Patients who undergo orthotopic liver transplantation often sustain acute kidney injury(AKI). 
The toll-like receptor 4(TLR4)/Nuclear factor-кB(NF-кB) pathway plays a role in AKI. 
Dexmedetomidine(Dex) has been shown to attenuate AKI. The current study aimed to determine 
whether liver transplantation-induced AKI is associated with inflammatory response, and to assess 
the effects of dexmedetomidine pretreatment on kidneys in rats following orthotopic autologous 
liver transplantation(OALT). Seventy-seven adult male rats were randomized into 11 groups. 
Kidney tissue histopathology and levels of blood urea nitrogen(BUN) and serum creatinine(SCr) 
were evaluated. Levels of TLR4, NF-κB, tumor necrosis factor-α, and interleukin-1β levels were 
measured in kidney tissues. OALT resulted in significant kidney functional impairment and tissue 
injury. Pre-treatment with dexmedetomidine decreased BUN and SCr levels and reduced kidney 
pathological injury, TLR4 expression, translocation of NF-κB, and cytokine production. The effects of 
dexmedetomidine were reversed by pre-treatment with atipamezole and BRL44408, but not ARC239. 
These results were confirmed by using α2A-adrenergic receptor siRNA which reversed the protective 
effect of dexmedetomidine on attenuating NRK-52E cells injury induced by hypoxia reoxygenation. 
In conclusion, Dexmedetomidine-pretreatment attenuates OALT-induced AKI in rats which may be 
contributable to its inhibition of TLR4/MyD88/NF-κB pathway activation. The renoprotective effects 
are related to α2A-adrenergic receptor subtypes.
Orthotopic liver transplantation (OLT) is the most effective therapy for end stage liver disease1. 
However, postoperative acute kidney injury (AKI) is a common and severe complication following OLT. 
Approximately 30–50% of patients undergoing liver transplantation have reportedly developed AKI2, 
which could adversely affect patient survival. Mechanisms that contribute to this complication remain 
unclear3. In addition, there are no effective and preventative treatment strategies to combat AKI fol-
lowing OLT. Therefore, there is a need to explore underlying mechanisms of AKI, and develop effective 
strategies for renal protection.
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There are many causes of AKI following OLT, which involve multiple factors. Among these factors, 
renal ischemia–reperfusion injury (IRI) caused by perioperative renal hypoperfusion is considered as one 
of the most important independent risk factors4–6. The specific mechanism of renal IRI remains unclear. 
However, many theories have been proposed. Recent reports have indicated that ischemia-reperfusion 
(I/R) is associated with an inflammatory cascade and polymorphonuclear neutrophil (PMN) activation7,8. 
Endothelial injury and dysfunction following renal ischemia has been shown to result in large releases of 
inflammatory mediators and adhesion molecules such as interleukin (IL)-1, IL-6, IL-8, tumor necrosis 
factor (TNF)-α , P-selectin, E-selectin, intercellular adhesion molecule (ICAM)-1, etc. These cytokines 
induce tubular epithelial cell necrosis and renal tubular atrophy9. Recent studies have demonstrated that 
the toll-like receptor (TLR4)/Nuclear factor-кB (NF-кB) pathway plays a dominant role in mediating 
deleterious effects in renal IRI10–12. Several studies13 have demonstrated that TLR4 expressions increased 
in renal tubular epithelial cells after renal ischemia.
Dexmedetomidine (Dex) is a highly selective agonist of α 2-adrenergic receptors, which is widely 
used in clinical anesthesia14. Beneficial effects of Dex include effective sedation, analgesia, hemody-
namic stabilization, as well as anti-inflammatory and diuretic effects without respiratory depression and 
drug-dependency issues15. In addition, Dex has been shown to ameliorate IRI in several organs including 
brain, heart and kidney through anti-inflammatory, anti-apoptotic or anti-oxidative effects16–19. Several 
studies have demonstrated that dexmedetomidine may inhibit inflammatory mediator levels includ-
ing IL-1, IL-6 and TNF-α 20–22. However, few studies have been conducted on the mechanism of its 
anti-inflammatory effects. Therefore, this study aims to observe the renal protective effects of Dex to 
explore its relevant mechanisms, and to determine which adrenoceptor subtype mediates this effect.
Results
General parameters. There was no significant difference in weight and time of anhepatic phase 
between any of the groups (P > 0.05). (Table 1)
Dex, atipamezole, BRL44408 and ARC239 had no effect on normal kidney function and his-
tology. Rats treated with Dex, atipamezole, BRL44408 or ARC239 without OALT all revealed no sig-
nificant changes in blood urea nitrogen (BUN) and serum creatinine (SCr) levels compared with the 
S group. Dex, atipamezole, BRL44408 and ARC239 also had no effect on morphology and histological 
scores of normal kidneys.
Dexmedetomidine reduced remote kidney function impairment in a dose-dependent man-
ner. Rats that underwent OALT-induced AKI (M group) exhibited significant kidney damage as 
reflected by the significant increase in BUN and SCr concentrations, compared with sham-operated rats 
(S group) (P < 0.05, Fig. 1A,B).
Compared with the M group, BUN and SCr levels were significantly reduced in groups pre-treated 
with dexmedetomidine, especially in D2 group with high doses of dexmedetomidine (P < 0.05); D1 
group (P < 0.05) and D2 group (P < 0.05) (Fig. 1A,B).
Dexmedetomidine dose-dependently attenuates I/R-mediated renal pathological 
injury. Kidneys taken from sham-operated rats (Fig. 2A) had normal tubular histology. Rats that under-
went OALT demonstrated severe acute tubular damage. These features included tubular cell swelling, 
Group Weight (g)
Time of anhepatic phase 
(minute)
S group 241.3 ± 18.1 –
M group 240.6 ± 15.0 19.9 ± 0.5
D1 group 234.1 ± 20.3 19.8 ± 0.8
D2 group 240.5 ± 16.8 20.0 ± 0.6
B1 group 243.4 ± 21.6 20.0 ± 0.7
B2 group 243.1 ± 17.5 20.1 ± 0.6
B3 group 239.9 ± 21.0 20.2 ± 0.5
C1 group 242.6 ± 13.0 –
C2 group 240.3 ± 16.5 –
C3 group 241.4 ± 21.6 –
C4 group 237.9 ± 21.0 –
Table 1.  weight and time of anhepatic phase between any of the groups. Weight and time of anhepatic 
phase (n = 7, x ± SD). There were no significant differences in weight and time of anhepatic phase.
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Figure 1. Alterations in (A) plasma urea and (B) plasma creatinine concentrations during OALT with 
the presence of dexmedetomidine (10 μg/kg for the D1 group and 50 μg/kg for the D2 group). Data are 
represented as mean ± standard deviation, n = 7. ▲P < 0.01 vs. S group, ■P < 0.01 vs. M group, and ♦P < 0.01 
vs. D2 group.
Figure 2. Histological analysis of tubulointerstitial injury and histological scores of kidneys. (A) S 
group, (B) M group, (C) D1 group, (D) D2 group, (E) B1 group, (F) B2 group, (G) B2 group, and (H) 
histological scores of various groups. Data are represented as means ± standard deviation, n = 7. ▲P < 0.01 
vs. S group, ■P < 0.01 vs. M group, and ♦P < 0.01 vs. D2 group.
www.nature.com/scientificreports/
4Scientific RepoRts | 5:16849 | DOI: 10.1038/srep16849
tubular dilatation and nuclear condensation (Fig. 2B). Dexmedetomidine decreased I/R-induced tubular 
damage (Fig. 2C,D).
Histological scores of rats in the M group were significantly higher than S group (P < 0.05). Histological 
scores significantly decreased in D1 and D2 groups, especially in D2 group, compared with scores in the 
M group (P < 0.05). However, these scores were still higher than S group (P < 0.05) (Fig. 2H).
Dexmedetomidine reduces proinflammatory cytokine generation in kidney tissues of rats 
following OALT. ELISA assays were performed to evaluate I/R-induced changes in TNF-α and IL-1β 
levels in kidneys, and to determine whether pre-treatment with dexmedetomidine could reduce inflam-
mation. Results presented here revealed that TNF-α levels in the M group significantly increased, com-
pared with the S group (P < 0.05, Fig. 3A). Pre-treatment with Dex in D1 and D2 groups significantly 
inhibited IRI-induced upregulation of TNF-α production (P < 0.05, Fig. 3A). Our results also revealed 
that TNF-α levels were inhibited by dexmedetomidine in a dose-dependent manner. Proinflammatory 
cytokine levels were lower in the D2 group (50 μ g/kg of Dex) than in the D1 group (10 μ g/kg of Dex) 
(P > 0.05, Fig. 3A). Similar results were observed for IL-1β levels (P < 0.05, Fig. 3B).
Dexmedetomidine regulates OALT-induced inflammatory responses by blocking TLR4/NF-κB 
pathway activation. Since TLR4/NF-κ B/p65 pathways have been shown to be closely associated 
with inflammation, we investigated whether dexmedetomidine exerts its effects through these signaling 
pathways. Western blotting revealed that TLR4 protein was low expression in the S group. TLR4 expres-
sion in renal tissues in the M group was significantly higher than S group (P < 0.05, Fig. 4A). I/R-induced 
TLR4 expressions were significantly inhibited in D1 and D2 groups (P < 0.05, Fig. 4B).
Immunofluorescence-staining and western blotting demonstrated that NF-κ B was mainly in the 
nuclei of tubules of the renal cortex in the M group (P < 0.05, Figs 4C,D and 5). Immunofluorescence 
and western blotting results revealed that nuclear translocation levels of NF-κ B in the M group were 
significantly up-regulated, compared with the S group (P < 0.05, Figs 4C,D and 5); and dexmedetomidine 
significantly decreased NF-κ B activation induced by OALT (P < 0.05, Figs 4C,D and 5).
Dexmedetomidine attenuats renal injury of the rats following OALT by activation of the 
a2A adrenergic receptor subtype. Effects of α2-adrenoceptor antagonists on decrease in I/R-induced 
renal injury by dexmedetomidine. As previously shown, dexmedetomidine significantly attenuated kid-
ney damage which manifested as the significant decrease in BUN and SCr concentrations (Fig.  1A,B). 
Moreover, both atipamezole (a non-selective α 2-antagonist) and BRL44408 (a α 2A-subtype adrenoceptor 
antagonist) reversed the protective effect of dexmedetomidine on renal injury. However, ARC239 (a 
α 2B-subtype adrenoceptor antagonist) did not block the protective effect of dexmedetomidine on kidneys 
(Fig. 1A,B).
Similar results were observed in histological analyses of tubulointerstitial injuries and histological 
scores of kidneys. Scores in B1 and B3 groups were higher than D2 group (P < 0.05, Fig. 2). However, 
scores in the B2 group were similar to scores in the D2 group (P > 0.05, Fig. 2).
Effects of α2-adrenoceptor antagonists on dexmedetomidine -induced inhibition of TLR4/NF-κB-inflammatory 
factor signaling pathway activation caused by OALT. As shown above, TLR4/NF-κ B-inflammatory fac-
tor signal pathway was activated following OALT (M group). However, this phenomenon was attenuated 
Figure 3. Effects of dexmedetomidine on OALT-induced upregulation of TNF-α and IL-1β levels in 
kidney tissue. Kidney tissues samples were taken at eight hours after liver reperfusion. Data are represented 
as means ± standard deviation, n = 7. ▲P < 0.01 vs. S group, ■P < 0.01 vs. M group, and ♦P < 0.01 vs. D2 
group.
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by dexmedetomidine (D1 and D2 groups). In addition, the effect of dexmedetomidine was reversed by 
atipamezole and BRL44408, but not by ARC239. (Figs 3,4 and 5)
α2A-adrenergic receptor knockdown reversed the protection effects of dexmedetomidine on preventing NRK-
52E cells from HR injury. siRNA administration, as a gradually mature technology, was used in our 
current study to knock down α 2A-adrenergic receptor(AR) induction. First, in NRK-52E cell line, we 
tested three α 2A-AR siRNA sequences and determined that sequence 1 was the most effective in inhib-
iting α 2A-AR mRNA expression (Fig.  6A). Then, we confirmed that effective knock down of α 2A-AR 
expression in NRK-52E cells exposed to H/R and/or Dex. α 2A-AR siRNA significantly increased cell 
damage following H/R, evidenced by increased LDH release (Fig.  6B). Next, TLR4, NF-κ B p65 and 
cytokines(TNF-α and IL-1β ) as important indexes of TLR4/NF-κ B pathway, were assessed to verify the 
effects of Dex on TLR4/NF-κ B signaling transduction. As shown in Fig. 6C–F, TLR4, NF-κ B p65 nuclear 
translocation and cytokines was significantly increased in H/R group (P < 0.05 vs. sham) while signifi-
cantly decreased with Dex treatment (P < 0.05). However, this protective effect of Dex was reversed by 
α 2A-AR knock down by siRNA, evidenced by the higher expression of TLR4 and NF-κ B, and more LDH 
and cytokines release in the H/R + α 2A-AR siRNA + Dex group than the H/R + Dex group (P < 0.05, 
Fig. 6C–F).
Discussion
OLT-AKI is one of the most important factors that affect prognosis, and often results in increased mor-
bidity. However, its specific mechanism remains unclear23. The pathophysiology of OLT is complex; 
which includes perioperative hypotension24, as well as occlusion of the portal vein (PV) and inferior 
vena cava (IVC), resulting in renal I/R4,5. This is considered as one of the most important independent 
risk factors of AKI. In addition, cyanotic kidney and intestinal endotoxemia induced by occlusion of 
IVC and remote kidney damage induced by liver transplantation25 could give rise to OLT-induced AKI26.
The current rat model closely simulated most procedures in liver transplantation including occlusion 
of the superior vena cava (SVC), IVC and PV, as well as cold liver protection, fluid perfusion, liver IRI 
and passive intestinal congestion27–29. In addition, compared with allogenic OLT, this rat AOLT model 
has advantages such as avoiding transplant rejection, reproducibility, and high survival of rats.
Figure 4. Dexmedetomidine downregulated TLR4 and NF-кB protein expressions after OALT:  (A) 
representative Western blotting for TLR4 in total proteins, (B) densitometric analysis of TLR4 protein 
expressions were normalized to β-actin content; (C) representative Western blotting for NF-кB P65 in 
nuclear proteins, (D) densitometric analysis of NF-кB P65 protein expressions were normalized to H3A 
content; and data are represented as means ± standard deviation. ▲P < 0.01, △P < 0.05 vs. S group; 
■P < 0.01, □P < 0.05 vs. M group; ♦P < 0.01, ◇P < 0.05 vs. D2 group.
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It is known that BUN and SCr serum levels, as well as kidney pathological changes, could reflect 
kidney damage. Occlusion and open of the PV and IVC result in renal IRI; in which, cytokines enters 
the blood circulation and damage remote organs and systems. These cytokines could induce tubular epi-
thelial cell necrosis and renal tubular atrophy; and further lead to renal function injury. In this current 
study, kidney function was found damaged in the M group, suggesting the presence of AKI induced by 
OALT. This study also demonstrated that this OALT model is suitable for research purposes.
As a member of the family of transmembrane proteins, TLR4 acts as a signal transduction molecule, 
which mainly expresses in human kidneys, myocardial cells, enterocytes, etc30. TLR4 uses four adap-
tors, including MyD88, TIRAP, TRIF and TRAM. TLR4-mediated signaling pathways mainly stimulate 
NF-κ B activation31. The signaling of TLR4 is largely divided into two pathways: MyD88-dependent and 
TRIF-dependent which commonly activate the canonical NF-kB pathway for the induction of inflamma-
tory cytokines. The NF-κ B heterodimer consists of p50 and p65 (Rel A) subunits and it is a nuclear tran-
scription factor that recognizes a common consensus DNA sequence which regulates a large number of 
target genes. It plays a pivotal role in immune and inflammatory responses by regulating the expression 
of several proteins including pro-inflammatory cytokines, chemokines and adhesion molecules; which 
further activates the NF–κ B pathway and aggravates renal injury from ischemia/reperfusion11. Recent 
studies have demonstrated that the TLR4/NF-κ B pathway plays an important role in mediating deleteri-
ous effects in renal injury from ischemia/reperfusion11,12. A recent study by Wu et al.13 demonstrated that 
TLR4-deficient and adaptor molecule myD88-deficient mice were protected from both kidney dysfunc-
tion and histological damage induced by renal IRI. In this present study, a significant increase in renal 
TLR4 expression, NF-κ B activity, as well as in IL-1β and TNF-α levels in kidney tissues, were observed 
in the M group, compared with the S group; indicating that renal TLR4/NF-κ B pathway was activated 
and downstream cytokines were synthesized following OALT, which further led to renal inflammatory 
damage. In the current study, nuclear localization of p65 appear to present both in tubular epithelial 
Figure 5. Representative confocal microscopic images shows the localization of NF-κB p65 by 
indirect immunofluorescence staining. (A) S group; (B) M group; (C) D1 group; (D) D2 group; (E) 
B1 group; (F) B2 group; (G) B3 group and (H). The proportion of P65 positive cells in tubular epithelial 
cells or glomerular cells. The expression of P65 in kidney tissues of different groups was detected by 
immunofluorescence staining under a laser scanning confocal microscope. Blue corresponds to nuclear 
staining and green corresponds to NF-κ B p65 staining. Original magnification under × 400. Red arrows 
indicate P65 positive glomerular cells, white arrow indicate P65 positive tubular epithelial cells, and yellow 
arrow points at interstitial cells.
www.nature.com/scientificreports/
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cells, glomerular cells and interstitial cells as shown in Fig. 5. This finding is in line with previous stud-
ies32–37 which showed that upregulation of expression of cytokines or activation of NF-κ B in glomeruli, 
renal tubules, and the peritubular interstitium were detected during the acute kidney injury induced by 
ischemia reperfusion injury. These suggest that interstitial cells (such as morphologies, resident leuko-
cytes/monocytes) may also play an important role in the acute kidney injury, which deserved further 
study. In the future, we should consider to isolate the primary cells of each type of renal cells and explore 
their relative role in the development of acute kidney injury.
Dexmedetomidine has been shown to have an organ protection effect. Kocoglu et al.16 revealed that 
dexmedetomidine was effective in protecting against cardiac IRI in rats. Hoffman et al.17 found that 
dexmedetomidine has a neuroprotective effect in rats. Kocoglu et al.18 and Frumento et al.19 revealed that 
dexmedetomidine could alleviate renal IRI. Recent studies38–40 found that dexmedetomidine could exert 
potential protective anti-inflammatory effects by reducing inflammatory cytokine serum levels. However, 
its upstream mechanisms have not been clearly revealed41,42.
This current study revealed that dexmedetomidine pretreatment, especially in high doses, prevents 
OALT induced pathological and functional injury to kidneys. These results indicate that the renal protec-
tion of dexmedetomidine was dose-dependent, which were consistent with previous reports. We propose 
that dexmedetomidine decreases inflammatory responses in kidney tissues of OALT rats by suppressing 
the TLR4/NF-κ B pathway. Interestingly, our results are consistent with a previous report conducted by 
Wu et al.43, which documented that dexmedetomidine downregulated TLR4/MyD88/NF-κ B pathway in 
rat lung tissues in response to LPS, suggesting that TLR4/MyD88/NF-κ B pathway may be the target of 
dexmedetomidine in conferring organ protection.
Previous studies have shown that α 2 agonist-induced sedation, analgesia, hypotension and hypo-
thermia are mediated by the α 2A-subtype44. The α 2C-subtype mediates startle reflex, stress response 
and locomotion. The hypertensive and peripheral hyperalgesic effect of norepinephrine is mediated 
by the α 2B-subtype45. Dexmedetomidine is a highly specific α 2-adrenoceptor agonist with high affin-
ity to each of the α 2-adrenoceptor subtypes. Previously, it has been revealed that the organ protective 
effect of Dexmedetomidine was mediated by the α 2A-adrenoceptor subtype. Ma et al.46 and Paris et 
al.39 discovered that dexmedetomidine was neuroprotective, and that this action was mediated by the 
Figure 6. Effects of Dex (1 nM) and knockdown of α-2A adrenergic receptor on H/R-induced cell 
damage in NRK52E cells. (A) Determine of specific α -2A adrenergic receptor siRNA cassettes. (B) Relative 
lactate dehydrogenase (LDH) release of NRK-52E cells. (C) Determine of TLR4 expression by western blot. 
(D) Determine of nuclear NF-κ B expression by western blot. (E) TNF-α release of NRK-52E cells. (F) IL-1β 
release of NRK-52E cells. Bars are mean ± standard deviation from four independent experiments. *P < 0.05 
vs. control group; #P < 0.05 vs. H/R group; $P < 0.05 vs. HR + DEX group.
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α 2A-adrenoceptor subtype. Ibacache et al.40 revealed that dexmedetomidine had myocardial protective 
effects by stimulating the α 2C-adrenoceptor subtype. In our present study, we focused on the classical 
inflammation pathway and we did find that Dex affected this pathway in OALT-induced AKI, which 
has been confirmed by using NRK-52E cell line to show dexmedetomidine directly suppress the TLR4/
NF-κB pathway activation mostly via adrenoceptor alpha 2A receptor.
These findings should jointly support our concept/conclusion that inhibition of TLR4/MyD88/NF-κ B 
pathway activation may represent a major mechanism whereby dexmedetomidine reduces acute kidney 
injury after orthotopic autologous liver transplantation. However, further study incorporating the use of 
gene knock-out mice for TLR4, MyD88 and/or NF-κ B should be performed in order to confirm the role 
of TLR4/MyD88/NF-κ B pathway activation in dexmedetomidine mediated attenuation of acute kidney 
injury after orthotopic autologous liver transplantation. There are some limitations in this current study. 
The effect of post-treatment with dexmedetomidine was not determined. In addition, TLR4 mRNA levels 
by PCR were not provided. Further research is needed to explore these areas.
Conclusions
In summary, these results substantiated our hypothesis that inflammatory reaction triggered by fluctu-
ating hemodynamic changes and severe liver IRI contributed to OALT-induced AKI. Dexmedetomidine 
pre-treatment resulted in a renal protective effect during OALT. The potential mechanism for this effect 
is through inhibiting renal inflammation by suppressing TLR4/NF-κ B inflammatory factor pathway acti-
vation. This effect was mediated by activating the α 2A-adrenergic receptor subtype. The properties of 
dexmedetomidine may decrease the mortality rate of OALT rats. It should be noted that dexmedeto-
midine has been proved to preserve renal blood flow in number of pathophysiological status47, which 
may have contributed, in part, to dexmedetomidine mediated attenuation of acute kidney injury after 
orthotopic autologous liver transplantation and deserves further study. However, the pathway of TLRs is 
complicated, and the mechanisms by which these observed results occur require further investigation.
Methods
Chemicals. Dexmedetomidine (Hengrui, Jiangsu, China), atipamezole (Sigma-Aldrich, USA), 
BRL44408 (Sigma-Aldrich, USA), and ARC239 (Santa Cruz, USA) were dissolved in 0.9% saline at 2.5 μ g/
ml, 25 μ g/ml, 50 μ g/ml and 2.5 μ g/ml concentrations, respectively. Heparin (Chen Xin Pharmaceutical 
Co., Ltd., Shandong, China) was diluted in 0.9% saline or acetic acid Ringer’s solution at 25 U/ml; and 
12.5 U/ml of protamine sulfate (KaiYue Pharmaceutical Co. Ltd., Beijing, China) was diluted in saline at 
0.05% concentration.
Animal preparation and groupings. Experimental protocols and design were approved by the Sun 
Yat-sen University Animal Experimentation Committee. Animal care was performed according to Sun 
Yat-sen University Guidelines for Animal Experimentation. Male Sprague–Dawley rats (250  ± 30 g) were 
obtained from Guangdong Medical Experimental Animal Center (Guangzhou, China). In all experi-
ments, all rats were maintained under standard conditions (room temperature at 25–27 °C with 12-hour 
light/dark cycle) with free access to specific pathogen-free (SPF) laboratory diet and distilled water for 
one week before the start of the experiment. Food was withheld 12 hours before the start of experiments, 
but all animals had free access to water.
A total of 77 rats were randomized into 11 groups (n = 7 per group) using a random number table, 
taking into consideration the weight of rats.
(1) Rats in the S group (sham-operated group) were subject to abdominal incision, vascular dissection 
and wound closure without hepatic vascular exclusion and perfusion.
(2) Rats in the M group (model group, established OALT model) underwent OALT operation including 
portal vein (PV) and inferior vena cava (IVC) occlusion for 20 minutes, followed by reperfusion for 
eight hours.
(3) Based on the previous studies48–50, rats in the D1 group (10 μ g/kg of Dex + OALT group) received 
10 μ g/kg of Dex injected intraperitoneally (i.p.) 30 minutes prior to OALT.
(4) Based on the previous studies48–50, rats in the D2 group (50 μ g/kg of Dex + OALT group) received 
50 μ g/kg of Dex injected i.p. 30 minutes prior to OALT.
(5) Based on the previous studie38,48–50, rats in the B1 group (atipamezole + OALT group) received ati-
pamezole (a non-specific inhibitor of α 2-adrenergic receptors) at 500 μ g/kg injected i.p. 40 min prior 
to OALT, followed by 50 μ g/kg of Dex injected i.p. 30 minutes prior to OALT.
(6) Based on the previous studies38,48–52, rats in the B2 group (ARC-239 + OALT group) received ARC239 
(a relative specific inhibitor of α 2B-adrenergic receptors) at 50 μ g/kg injected i.p. 40 minutes prior to 
I/R, followed by 50 μ g/kg of Dex injected i.p. 30 minutes prior to OALT.
(7) Based on the previous studies38,48–52, rats in the B3 group (BRL44408 + OALT group) received 
BRL44408 (a relatively specific inhibitor of α -2a-adrenergic receptors) at 1.5 mg/kg injected i.p. 
40 minutes prior to OALT, followed by 50 μ g/kg of Dex injected i.p. 30 minutes prior to OALT.
(8) Rats in the C1 group received 50 μ g/kg of Dex injected i.p.
(9) Rats in the C2 group received 500 μ g/kg of atipamezole injected i.p., followed by 50 μ g/kg of Dex 
injected i.p.
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(10) Rats in the C3 group received 50 μ g/kg of ARC239 injected i.p., followed by 50 μ g/kg of Dex injected 
i.p.
(11) Rats in the C4 group received 1.5 mg/kg of BRL44408 injected i.p., followed by 50 μ g/kg of Dex 
injected i.p.
Establishment of rat OALT model. Rats were anesthetized with isoflurane (The Third Affiliated 
Hospital of Sun Yat-sen University, Guangzhou, China). Then, rat OALT models were established as 
previously described by Chi et al.53, and modified by Yao et al.54. This model simulated the main surgical 
steps and pathophysiological course of human liver transplantation including blocking and unclamping 
of the hepatic artery and portal vein, liver IRI, intestinal congestion, and hypoxia.
Animals were sacrificed eight hours after reperfusion based on previous experiments in rats, which 
demonstrated that kidney injury was most serious eight hours after reperfusion55. Kidney tissues were 
removed for histopathological evaluation, Western blotting, immunofluorescence analysis, and ELISA; 
while blood samples were taken from the abdominal aorta eight hours after liver reperfusion for blood 
urea nitrogen (BUN) and serum creatinine (SCr) measurements.
Cell Culture. NRK-52E cells (kidney tubular epithelial cells) were obtained from American Type 
Culture Collection (Manassas, VA) and cultured in Dulbecco’s Modified Eagle’s Medium/F-12 supple-
mented with 10% fetal bovine serum. Cells were grown at 37 °C in an atmosphere of 5% CO2 in air.
H/R protocol. The H/R protocol was performed as previously described with modifications56. Briefly, 
for hypoxia, confluent cells were incubated for 24 hours in an anaerobic chamber equilibrated with 5% 
CO2 and 95% N2. A metal catalyzer (Engelhard, USA) was used to maintain a constant low oxygen 
concentration (< 0.1%) in the chamber. After the hypoxia treatment, the cells were transferred back to a 
regular incubator with 21% oxygen for 4 hours.
Dexmedetomidine and siRNA preparation, screening and deliver. NRK-52E cells were conflu-
ent and pretreated with Dex at clinically relevant concentrations (1 nM)57 for 1 h immediately followed 
by the H/R treatment. Three siRNA duplexes targeting adrenoceptor alpha 2A rat gene (GenBank acces-
sion ID: 25083) were designed using the siRNA Target Finder and Design Tool available at http://www.
ambion.com and were commercially obtained from Biomics (Jiangsu, China). Green fluorescent protein 
(GFP) siRNA, with no homology to adrenoceptor alpha 2A gene, was taken as siRNA control. After 
transfection using Lipofectamine® 3000 transfection reagent (Life technologies) and incubation for 48 
hrs, NRK-52E cells were harvested and expression of adrenoceptor alpha 2A mRNA level was detected 
by real time PCR (RT-PCR). Adrenoceptor alpha 2A siRNA that had the maximum inhibition rate was 
selected in our vitro experiments.
Adrenoceptor alpha 2A siRNA1,
5′ -CGAGCUGCAAGAUUAACGA dTdT-3′ (sense),
3′ -dTdT GCUCGACGUUCUAAUUGCU-5′ (antisense);
Adrenoceptor alpha 2A siRNA2,
5′ -CUGGUUAUUAUCGCAGUGU dTdT-3′ (sense),
3′ -dTdT GACCAAUAAUAGCGUCACA-5′ (antisense);
Adrenoceptor alpha 2A siRNA3,
5′ -CUUUGGCCAACGAGGUUAU dTdT-3′ (sense),
3′ -dTdT GAAACCGGUUGCUCCAAUA-5′ (antisense).
Lactate dehydrogenase (LDH) assay. Cells were seeded at low density (10,000 cells/cm2) in 96-well 
plates. At the end of different stimulation, LDH assays was carried out according to the manufacturer’s 
introduction (Roche Diagnostics, Indianapolis, USA) as described in the study of Luo C et al.55.
Kidney histopathological evaluation. Kidney specimens were fixed in 10% buffered formalin and 
embedded in paraffin. Half of the paraffin-embedded kidney tissues were cut into 5-μ m sections for his-
topathological analysis using hematoxylin–eosin staining. The remaining half of the kidney tissues and 
contralateral kidney cortex samples were immediately frozen in liquid nitrogen for protein quantitative 
assay and immunohistochemical analysis. Severity of the kidney injury was evaluated by two histologists 
who were initially blinded to the experiment. A semi-quantitative scale was used in evaluating the mor-
phological characteristics of tubules as suggested by Hamer’s standard et al.58.
Biochemical analysis. Serum was isolated from blood by centrifugation (1,500 rpm at 4 °C for 
10 minutes). BUN and SCr were analyzed as indicators of impaired glomerular function with an auto-
matic biochemistry analyzer (Watford Olympus AU640, UK), based on manufacturer’s instructions.
TLR4 and NF-кB p65 analysis by Western blotting. Kidney tissue or NRK-52E cells were ground 
and homogenized with a protein lysis solution (KeyGen BioTech, China). Nuclear and cytoplasmic pro-
teins were extracted by using nuclear and cytoplasmic extraction reagents according to the manufacture’s 
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instructions (Keygen Biotech. Co., LTD, Nanjing, China). The samples were separated by sodium dode-
cyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and electro-transferred onto a nitrocellu-
lose membrane. Subsequently, the membrane was blocked with 5% non-fat milk for two hours at room 
temperature, followed by overnight incubation with the rabbit polyclonal anti-TLR4 antibody (1:2,000, 
Santa Cruz Biotechnology, USA), the rabbit polyclonal anti-nuclear factor-kappa B (NF-kB) p65 anti-
body (1:500, Santa Cruz, USA), the rabbit polyclonal anti-Histone H3A polyclonal antibody (1:500, Santa 
Cruz, USA) and the rabbit polyclonal anti-β -actin (1:500, Santa Cruz, USA). The membrane was then 
washed and incubated with a secondary antibody (goat anti-rabbit IgG, HRP-linked antibody 1:4,000, 
Cell Signaling Biotechnology, USA) for two hours. Blotted protein bands were visualized by enhanced 
chemiluminescence (ECL) Western blotting detection reagents (Amersham, USA). Protein density meas-
urement was correlated to protein expressions, and normalized with respect to Histone H2A or β -actin 
band density.
Immunofluorescence analysis for NF-кB p65. NF-кB p65 in rat kidney was detected according 
to manufacturer’s instructions. Paraffin-embedded kidney sections were dewaxed and rehydrated. After 
three hours of antigen retrieval in 10 mM of sodium citrate (pH 6.0), the sections were incubated with 
blocking buffer (5% BSA in PBS) for one hour at room temperature; then, stained with NF-κ B p65 
(1:1,000, Santa Cruz Biotechnology, USA) at 4 °C overnight, followed by anti-rabbit IgG (1:1,000). To 
identify nuclei, tissues were counterstained with fluorescent dye DAPI for three minutes. In all cases, anti-
body negative controls were evaluated to ensure that results were not a consequence of cross-reactivity 
or non-specific binding of secondary antibodies. All images were measured using a Leica DM 4000 B 
scanning confocal microscope (Leica, USA). These sections were observed under a light microscope by 
an investigator who was initially blinded to the treatment groups, and 10 randomly selected fields of each 
slide were semi-quantified.
Enzyme-linked immunosorbent assay (ELISA) of cytokines. 100 mg wet kidney tissues were 
prepared as 10% tissue homogenates, and centrifuged at 3000 rpm at 4 °C for 10 min. The supernatant 
was collected for further analysis. The concentrations of TNF-α and IL-lβ in kidney tissue or in the 
cell culture medium were measured according to manufacturer’s instructions using ELISA kits (Nanjing 
Keygen Biotech Co., Ltd.). Absorbance at 450 nm (OD 450) was determined using a microplate reader.
Statistical analysis. All statistical analyses were performed with SPSS Version 12.0 (SPSS Inc., 
Chicago, IL, USA). Quantitative data are presented as mean ± standard deviation (SD). Multiple compar-
isons among groups were analyzed using repeated measures by one-way analysis of variance (ANOVA) 
when the datas were normally distributed and the variances of the groups are homogeneous. Otherwise, 
Wil coxon Rank-Sum test should be used. Least significant difference (LSD) was used to assess differ-
ences between groups. Chi-square test was carried out on count data. A two-tailed P value less than 0.05 
was considered statistically and significantly different.
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